Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression

Robert C. Hilton, Manivel Rengasamy, Brandon Mansoor, Jiayan He, Taryn Mayes, Graham J. Emslie, Giovanna Porta, Greg N. Clarke, Karen Wagner, Boris Birmaher, Martin B. Keller, Neal Ryan, Wael Shamseddeen, Joan Rosenbaum Asarnow, David A. Brent

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To assess the relative efficacy of antidepressant medication, alone and in combination with cognitive behavioral therapy (CBT), on comorbid symptoms of anxiety, attention, and disruptive behavior disorders in participants in the Treatment of Resistant Depression in Adolescents (TORDIA) trial. Method: Adolescents with selective serotonin reuptake inhibitor (SSRI)-resistant depression (N = 334) were randomly assigned to a medication switch alone (to another SSRI or to venlafaxine) or to a medication switch plus CBT. Anxiety, attention-deficit/hyperactivity disorder (ADHD), and disruptive behavior disorder (DBD) symptoms were assessed by psychiatric interview and self-report at regular intervals between baseline and 24 weeks. The differential effects of medication and of CBT, and the impact of remission on the course of comorbid symptoms and diagnoses, were assessed using generalized linear mixed models. Results: Remission was associated with a greater reduction in scalar measures of anxiety, ADHD, and DBDs, and a greater decrease in the rate of diagnosed anxiety disorders. The correlations between the changes in symptoms of depression on the CDRS-R and anxiety, ADHD, and oppositional symptoms were modest, ranging from r = 0.12 to r = 0.28. There were no significant differential treatment effects on diagnoses, or corresponding symptoms. Conclusion: The achievement of remission had a beneficial effect on anxiety, ADHD, and DBD symptoms, regardless of the type of treatment received. There were no differential effects of medication or CBT on outcome, except for a nonsignificant trend that those adolescents treated with SSRIs showed a greater decrease in rates of comorbid DBDs relative to those treated with venlafaxine. Clinical trial registration information - Treatment of SSRI-Resistant Depression In Adolescents (TORDIA); http://clinicaltrials.gov/; NCT00018902.

Original languageEnglish (US)
Pages (from-to)482-492
Number of pages11
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume52
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Behavioral Symptoms
Serotonin Uptake Inhibitors
Cognitive Therapy
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Anxiety
Depression
Treatment-Resistant Depressive Disorder
Therapeutics
Anxiety Disorders
Self Report
Antidepressive Agents
Psychiatry
Linear Models
Clinical Trials
Interviews

Keywords

  • antidepressants
  • cognitive behavioral therapy (CBT)
  • comorbidity
  • secondary outcomes
  • Treatment of Resistant Depression in Adolescents (TORDIA)

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression. / Hilton, Robert C.; Rengasamy, Manivel; Mansoor, Brandon; He, Jiayan; Mayes, Taryn; Emslie, Graham J.; Porta, Giovanna; Clarke, Greg N.; Wagner, Karen; Birmaher, Boris; Keller, Martin B.; Ryan, Neal; Shamseddeen, Wael; Asarnow, Joan Rosenbaum; Brent, David A.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 52, No. 5, 05.2013, p. 482-492.

Research output: Contribution to journalArticle

Hilton, RC, Rengasamy, M, Mansoor, B, He, J, Mayes, T, Emslie, GJ, Porta, G, Clarke, GN, Wagner, K, Birmaher, B, Keller, MB, Ryan, N, Shamseddeen, W, Asarnow, JR & Brent, DA 2013, 'Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 52, no. 5, pp. 482-492. https://doi.org/10.1016/j.jaac.2013.02.013
Hilton, Robert C. ; Rengasamy, Manivel ; Mansoor, Brandon ; He, Jiayan ; Mayes, Taryn ; Emslie, Graham J. ; Porta, Giovanna ; Clarke, Greg N. ; Wagner, Karen ; Birmaher, Boris ; Keller, Martin B. ; Ryan, Neal ; Shamseddeen, Wael ; Asarnow, Joan Rosenbaum ; Brent, David A. / Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2013 ; Vol. 52, No. 5. pp. 482-492.
@article{e837f99cf30b49b0aa163b7aad7ef55e,
title = "Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression",
abstract = "Objective: To assess the relative efficacy of antidepressant medication, alone and in combination with cognitive behavioral therapy (CBT), on comorbid symptoms of anxiety, attention, and disruptive behavior disorders in participants in the Treatment of Resistant Depression in Adolescents (TORDIA) trial. Method: Adolescents with selective serotonin reuptake inhibitor (SSRI)-resistant depression (N = 334) were randomly assigned to a medication switch alone (to another SSRI or to venlafaxine) or to a medication switch plus CBT. Anxiety, attention-deficit/hyperactivity disorder (ADHD), and disruptive behavior disorder (DBD) symptoms were assessed by psychiatric interview and self-report at regular intervals between baseline and 24 weeks. The differential effects of medication and of CBT, and the impact of remission on the course of comorbid symptoms and diagnoses, were assessed using generalized linear mixed models. Results: Remission was associated with a greater reduction in scalar measures of anxiety, ADHD, and DBDs, and a greater decrease in the rate of diagnosed anxiety disorders. The correlations between the changes in symptoms of depression on the CDRS-R and anxiety, ADHD, and oppositional symptoms were modest, ranging from r = 0.12 to r = 0.28. There were no significant differential treatment effects on diagnoses, or corresponding symptoms. Conclusion: The achievement of remission had a beneficial effect on anxiety, ADHD, and DBD symptoms, regardless of the type of treatment received. There were no differential effects of medication or CBT on outcome, except for a nonsignificant trend that those adolescents treated with SSRIs showed a greater decrease in rates of comorbid DBDs relative to those treated with venlafaxine. Clinical trial registration information - Treatment of SSRI-Resistant Depression In Adolescents (TORDIA); http://clinicaltrials.gov/; NCT00018902.",
keywords = "antidepressants, cognitive behavioral therapy (CBT), comorbidity, secondary outcomes, Treatment of Resistant Depression in Adolescents (TORDIA)",
author = "Hilton, {Robert C.} and Manivel Rengasamy and Brandon Mansoor and Jiayan He and Taryn Mayes and Emslie, {Graham J.} and Giovanna Porta and Clarke, {Greg N.} and Karen Wagner and Boris Birmaher and Keller, {Martin B.} and Neal Ryan and Wael Shamseddeen and Asarnow, {Joan Rosenbaum} and Brent, {David A.}",
year = "2013",
month = "5",
doi = "10.1016/j.jaac.2013.02.013",
language = "English (US)",
volume = "52",
pages = "482--492",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression

AU - Hilton, Robert C.

AU - Rengasamy, Manivel

AU - Mansoor, Brandon

AU - He, Jiayan

AU - Mayes, Taryn

AU - Emslie, Graham J.

AU - Porta, Giovanna

AU - Clarke, Greg N.

AU - Wagner, Karen

AU - Birmaher, Boris

AU - Keller, Martin B.

AU - Ryan, Neal

AU - Shamseddeen, Wael

AU - Asarnow, Joan Rosenbaum

AU - Brent, David A.

PY - 2013/5

Y1 - 2013/5

N2 - Objective: To assess the relative efficacy of antidepressant medication, alone and in combination with cognitive behavioral therapy (CBT), on comorbid symptoms of anxiety, attention, and disruptive behavior disorders in participants in the Treatment of Resistant Depression in Adolescents (TORDIA) trial. Method: Adolescents with selective serotonin reuptake inhibitor (SSRI)-resistant depression (N = 334) were randomly assigned to a medication switch alone (to another SSRI or to venlafaxine) or to a medication switch plus CBT. Anxiety, attention-deficit/hyperactivity disorder (ADHD), and disruptive behavior disorder (DBD) symptoms were assessed by psychiatric interview and self-report at regular intervals between baseline and 24 weeks. The differential effects of medication and of CBT, and the impact of remission on the course of comorbid symptoms and diagnoses, were assessed using generalized linear mixed models. Results: Remission was associated with a greater reduction in scalar measures of anxiety, ADHD, and DBDs, and a greater decrease in the rate of diagnosed anxiety disorders. The correlations between the changes in symptoms of depression on the CDRS-R and anxiety, ADHD, and oppositional symptoms were modest, ranging from r = 0.12 to r = 0.28. There were no significant differential treatment effects on diagnoses, or corresponding symptoms. Conclusion: The achievement of remission had a beneficial effect on anxiety, ADHD, and DBD symptoms, regardless of the type of treatment received. There were no differential effects of medication or CBT on outcome, except for a nonsignificant trend that those adolescents treated with SSRIs showed a greater decrease in rates of comorbid DBDs relative to those treated with venlafaxine. Clinical trial registration information - Treatment of SSRI-Resistant Depression In Adolescents (TORDIA); http://clinicaltrials.gov/; NCT00018902.

AB - Objective: To assess the relative efficacy of antidepressant medication, alone and in combination with cognitive behavioral therapy (CBT), on comorbid symptoms of anxiety, attention, and disruptive behavior disorders in participants in the Treatment of Resistant Depression in Adolescents (TORDIA) trial. Method: Adolescents with selective serotonin reuptake inhibitor (SSRI)-resistant depression (N = 334) were randomly assigned to a medication switch alone (to another SSRI or to venlafaxine) or to a medication switch plus CBT. Anxiety, attention-deficit/hyperactivity disorder (ADHD), and disruptive behavior disorder (DBD) symptoms were assessed by psychiatric interview and self-report at regular intervals between baseline and 24 weeks. The differential effects of medication and of CBT, and the impact of remission on the course of comorbid symptoms and diagnoses, were assessed using generalized linear mixed models. Results: Remission was associated with a greater reduction in scalar measures of anxiety, ADHD, and DBDs, and a greater decrease in the rate of diagnosed anxiety disorders. The correlations between the changes in symptoms of depression on the CDRS-R and anxiety, ADHD, and oppositional symptoms were modest, ranging from r = 0.12 to r = 0.28. There were no significant differential treatment effects on diagnoses, or corresponding symptoms. Conclusion: The achievement of remission had a beneficial effect on anxiety, ADHD, and DBD symptoms, regardless of the type of treatment received. There were no differential effects of medication or CBT on outcome, except for a nonsignificant trend that those adolescents treated with SSRIs showed a greater decrease in rates of comorbid DBDs relative to those treated with venlafaxine. Clinical trial registration information - Treatment of SSRI-Resistant Depression In Adolescents (TORDIA); http://clinicaltrials.gov/; NCT00018902.

KW - antidepressants

KW - cognitive behavioral therapy (CBT)

KW - comorbidity

KW - secondary outcomes

KW - Treatment of Resistant Depression in Adolescents (TORDIA)

UR - http://www.scopus.com/inward/record.url?scp=84876791765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876791765&partnerID=8YFLogxK

U2 - 10.1016/j.jaac.2013.02.013

DO - 10.1016/j.jaac.2013.02.013

M3 - Article

VL - 52

SP - 482

EP - 492

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 5

ER -